Scholarlink

<p>Tribbles pseudokinase (TRIB1, TRIB2, and TRIB3) are emerging as key modulators of cancer biology, despite lacking classical catalytic activity. Acting as molecular scaffolds and regulators of protein stability, TRIB proteins influence critical signaling pathways by orchestrating interactions between kinases, transcription factors, and ubiquitin ligases. Their ability to bridge phosphorylation and ubiquitination networks enables fine-tuned control over cell proliferation, differentiation, and survival. Recent studies have identified dysregulated TRIB expression and function across a wide range of malignancies, including leukemia, melanoma, lung, liver, breast, and prostate cancers. In particular, TRIB-mediated degradation of tumor suppressors and stabilization of oncogenic proteins has positioned these pseudokinases as central players in tumor initiation and progression. This review discusses the current insights into the structure, function, and oncogenic roles of TRIB proteins, highlighting their potential as diagnostic markers and novel therapeutic targets in cancer.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Tribbles (TRIB) pseudokinase in cancer: an emerging key player

  • 期刊论文

  • 发表日期：

    2025年11月20日

查看全文
  • Jeyrubini Ramesh,
  • Maheswaran Solayappan,
  • Aswani Jaishanker,
  • Reshvaanie Rajandran,
  • Geethanjali Rajasegaran,
  • Thevendran Ramesh,
  • Mot Yee Yik,
  • Adam Azlan,
  • Emmanuel Jairaj Moses

摘要

Tribbles pseudokinase (TRIB1, TRIB2, and TRIB3) are emerging as key modulators of cancer biology, despite lacking classical catalytic activity. Acting as molecular scaffolds and regulators of protein stability, TRIB proteins influence critical signaling pathways by orchestrating interactions between kinases, transcription factors, and ubiquitin ligases. Their ability to bridge phosphorylation and ubiquitination networks enables fine-tuned control over cell proliferation, differentiation, and survival. Recent studies have identified dysregulated TRIB expression and function across a wide range of malignancies, including leukemia, melanoma, lung, liver, breast, and prostate cancers. In particular, TRIB-mediated degradation of tumor suppressors and stabilization of oncogenic proteins has positioned these pseudokinases as central players in tumor initiation and progression. This review discusses the current insights into the structure, function, and oncogenic roles of TRIB proteins, highlighting their potential as diagnostic markers and novel therapeutic targets in cancer.